Table 3.

Results of univariate correlation of inflammation scores and cytokine levels with response and PFS under ICI treatment.

	PD vs. PR	Median PFS
NLR (≥ 5.2 vs. < 5.2)	p = 0.003	Median PFS 7.43 weeks [95% CI 3.37–11.49] vs. 40.0 weeks [95% CI 16.01–64.0], p < 0.001
SII (≥ 1217 vs. < 1217)	p = 0.011	Median PFS 7.51 weeks [95% CI 3.26–11.88] vs. 40.0 weeks [95% CI 11.48–68.52], p = 0.001
PLR (≥ 50 vs. < 50)	p = 0.035	Median PFS 11.71 weeks [95% CI 2.06–13.37] vs. 7.71 weeks [95% CI 0–25.71], p = 0.406
CRP (≥ 4.3 mg/dl vs. < 4.3 mg/dl)	p = 0.67	median PFS 7.57 weeks [95% CI 2.71–12.44] vs. 14.71 weeks [95% CI 4.18–25.25], p = 0.043
mGPS (0 vs. 1 vs. 2)	p = 0.453	Median PFS 15.14 weeks [95% CI 0–34.21] vs. 11.71 weeks [95% CI 2.94–20.49] vs. 7.57 weeks [95% CI NE], p = 0.204
IL-6 (≥ 11.6 pg/ml vs. < 11.6 pg/ml)	p < 0.001	Median PFS 5.14 weeks [95% CI 0.95–9.33] vs. 38.57 weeks [95% CI 8.45–68.69], p < 0.001
IL-8 (≥ 19.67 pg/ml vs. < 19.67 pg/ml)	p = 0.006	Median PFS 4.0 weeks [95% CI 2.71–5.29] vs. 19.71 weeks [95% CI 3.19–36.23], p = 0.030
IL-10 (≥ 19.4 pg/ml vs. < 19.4 pg/ml)	p = 0.842	Median PFS 2.57 weeks [95% CI NE] vs. 11.71 weeks [95% CI 2.86–20.57], p = NE
IFN-γ (≥ 16.7 pg/ml vs. < 16.7 pg/ml)	p < 0.001	Median PFS 40.0 weeks [95% CI 30.79–49.22] vs. 5.86 weeks [95% CI 2.20–9.51], p < 0.001
TNF-α (≥ 3.6 pg/ml vs. < 3.6 pg/ml)	p = 0.387	Median PFS 11.0 weeks [95% CI 5.50–16.50] vs. 7.43 weeks [95% CI 0–19.16], p = 0.207